Anlotinib Plus Nab-Paclitaxels and S-1 Versus FOLFOX for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment: a Phase 2/3, Multi-centric Double-stage Randomized Controlled Trial.

A clinical trial, NCT06662877, is being conducted to evaluate the efficacy of Anlotinib plus Nab-Paclitaxels and S-1 as a second-line treatment for advanced biliary tract cancer (BTC) compared to the standard FOLFOX regimen. The trial aims to improve treatment outcomes for patients with BTC, which has a low 5-year survival rate. The study will assess overall survival, progression-free survival, objective response rate, disease control rate, quality of life, and adverse events as primary and secondary outcome measures. The trial is set to start on November 25, 2024, with a primary completion date of September 1, 2029. [Extracted from the article]